

## 2016 Global life sciences outlook

### Sources

- <sup>1</sup> *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015
- <sup>2</sup> Ibid
- <sup>3</sup> *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015
- <sup>4</sup> Ibid
- <sup>5</sup> EIU data tool, accessed on September 9, 2015
- <sup>6</sup> EIU – Healthcare, United States of America, June 2015; Russia, June 2015; Brazil, June 2015; China, May 2015; Greece, September 2014; Japan, June 2015
- <sup>7</sup> *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015
- <sup>8</sup> Ibid
- <sup>9</sup> *2015 Big Pharma Outlook*, Datamonitor Healthcare, July 2015
- <sup>10</sup> *World Preview 2015, Outlook to 2020*, EvaluatePharma, June 2014
- <sup>11</sup> *Industry Report: Global Biotechnology*, IBISWorld, January 2015. Figure is the market size for all biotechnology products, including human health, animal health, crop production, etc.
- <sup>12</sup> *World Preview 2015, Outlook to 2020*, EvaluatePharma, June 2014
- <sup>13</sup> "Record fundraising bolsters UK's biotech challengers," *Financial Times*, July 21, 2015, <http://www.ft.com/intl/cms/s/0/4e03c962-2f9e-11e5-91ac-a5e17d9b4cff.html#axzz3o44xj5zM>. Accessed October 9, 2015
- <sup>14</sup> *Industry Report, Healthcare: China*, The Economist Intelligence Unit, May 2015, citing the *Generics and Biosimilars Initiative Journal*
- <sup>15</sup> *An introduction to value-based healthcare in Europe*, The Economist Intelligence Unit. Figure according to IMS Health
- <sup>16</sup> <http://bmjopen.bmj.com/content/4/5/e004623.long>
- <sup>17</sup> VII Conference of the Pan American Network for Drug Regulatory Harmonization (CPANDRH). Presentación - Estrategia de Liberación de Genéricos para el Ahorro de las Familias Mexicanas. Julio Sánchez y Tépoz. Cofepris, August 2013
- <sup>18</sup> *Brazil – Healthcare report: Pharma and biotech*, The Economist Intelligence Unit, July 6, 2015
- <sup>19</sup> *Medicines Outlook through 2017*, IMS Institute for Healthcare Informatics; excerpted from *Healthcare and Life Sciences Predictions 2020: A bold future?*, Deloitte U.K. Centre for Health Solutions, 2014
- <sup>20</sup> Allied Market Research, *Global Biosimilars/Follow-on Biologics Market*, July 2014, cited in *Winning with biosimilars: Opportunities in global markets*, Deloitte, 2015 [www.deloitte.com/us/globalbiosimilars](http://www.deloitte.com/us/globalbiosimilars)
- <sup>21</sup> *Nature Biotechnology* 32, 626-632 (2014)
- <sup>22</sup> "FDA approves first biosimilar drug Zarxio," U.S. Food and Drug Administration news release, March 6, 2015, <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm>. Accessed September 6, 2015
- <sup>23</sup> Ibid
- <sup>24</sup> "Sandoz launches sale of biosimilar Zarxio," *Modern Healthcare*, September 3, 2015, <http://www.modernhealthcare.com/article/20150903/NEWS/150909949>. Accessed September 6, 2015
- <sup>25</sup> Ibid
- <sup>26</sup> *Winning with biosimilars: Opportunities in global markets*, Deloitte, 2015 [www.deloitte.com/us/globalbiosimilars](http://www.deloitte.com/us/globalbiosimilars)
- <sup>27</sup> Ibid
- <sup>28</sup> *Winning with biosimilars: Opportunities in global markets*, Deloitte, 2015 [www.deloitte.com/us/globalbiosimilars](http://www.deloitte.com/us/globalbiosimilars)
- <sup>29</sup> Ibid
- <sup>30</sup> *World Preview 2015, Outlook to 2020*, EvaluateMedTech, September 2015
- <sup>31</sup> Ibid
- <sup>32</sup> Agarwal, A. Ressler, D. Snyder, G. "The current and future state of companion diagnostics," *Pharmacogenomics and Personalized Medicine*, Dove Press, March 31, 2015
- <sup>33</sup> *EP Vantage MedTech Half-Year Review 2015*, Evaluate Ltd., July 2015 <http://www.evaluategroup.com/public/Reports/EPVantage-MedTech-HalfYear-Review-2015.aspx>
- <sup>34</sup> Ibid
- <sup>35</sup> *EP Vantage MedTech Half-Year Review 2015*, Evaluate Ltd., July 2015 <http://www.evaluategroup.com/public/Reports/EPVantage-MedTech-HalfYear-Review-2015.aspx>
- <sup>36</sup> Ibid
- <sup>37</sup> *Next-generation "smart" MedTech devices: Preparing for an increasingly intelligent future*, Deloitte Center for Health Solutions, 2015, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/smart-medtech-increasingly-intelligent-future.html>
- <sup>38</sup> *EP Vantage MedTech Half-Year Review 2015*, Evaluate Ltd., July 2015 <http://www.evaluategroup.com/public/Reports/EPVantage-MedTech-HalfYear-Review-2015.aspx>
- <sup>39</sup> Ibid
- <sup>40</sup> "Medical devices: Council getting ready for talks with EP," press release, European Council, June 19, 2017, [www.consilium.europa.eu/en/press/press-releases/2015/06/19-medical-devices-council-ready-talk-with-ep](http://www.consilium.europa.eu/en/press/press-releases/2015/06/19-medical-devices-council-ready-talk-with-ep). Accessed October 10, 2015
- <sup>41</sup> Ibid
- <sup>42</sup> Juvenile Diabetes Research Foundation (JDRF), "\$1.9 billion potential healthcare saving for USA with artificial pancreas," June 2011, <https://www.jdrf.org.uk/news/latest-news/19-billion-potential-healthcare-saving-for-usa-with-artificial-pancreas>, accessed February 2015. Excerpted from *Next-generation "smart" MedTech devices: Preparing for an increasingly intelligent future*, Deloitte Center for Health Solutions, 2015
- <sup>43</sup> *Global Pharmaceuticals Wholesale and Distribution Market 2015-2019*, TechNavio Insights, Infiniti Research Ltd., 2014
- <sup>44</sup> Ibid
- <sup>45</sup> *Global Pharmaceuticals Wholesale and Distribution Market 2015-2019*, TechNavio Insights, Infiniti Research Ltd., 2014
- <sup>46</sup> Ibid
- <sup>47</sup> *Global Pharmaceuticals Wholesale and Distribution Market 2015-2019*, TechNavio Insights, Infiniti Research Ltd., 2014

48 Ibid

49 *Global Pharmaceuticals Wholesale and Distribution Market 2015-2019*, TechNavio Insights, Infiniti Research Ltd., 2014

50 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

51 *Brazil Pharmaceuticals & Healthcare Report - Pharmaceutical - Q4 2015*, BMI Research, August 25, 2015. (The report was downloaded from ISI Emerging Markets [Intellinet])

52 *Mexico Pharmaceuticals & Healthcare Report - Pharmaceutical - Q4 2015*, BMI Research, 28 July 2015. (The report was downloaded from ISI Emerging Markets [Intellinet])

53 *Development trends and practical aspects of the Russian pharmaceutical industry – 2014*, Deloitte, 2014  
<https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-health-care/russia-pharmaceutical-industry-2014.pdf>

54 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

55 Ibid

56 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

57 Ibid

58 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

59 "Obamacare enrollees must double to make budget projections work," *The Washington Times*, September 13, 2015, <http://www.washingtontimes.com/news/2015/sep/13/obamacare-enrollees-must-double-to-make-budget-pro/>. Accessed September 15, 2015

60 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

61 Ibid

62 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

63 *Tax services for the life sciences industry*, Deloitte, 2015

64 Ibid

65 *BEPS: Frequently asked questions and answers*, Deloitte, June 2015

66 Ibid

67 *BEPS: Frequently asked questions and answers*, Deloitte, June 2015

68 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

69 Ibid

70 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

71 *An introduction to value-based healthcare in Europe*, The Economist Intelligence Unit

72 Ibid

73 *An introduction to value-based healthcare in Europe*, The Economist Intelligence Unit

74 "India's NPPA extends pricing policy on drugs, adding fuel to price cap fire," *FiercePharma*, December 12, 2014, <http://www.fiercepharma.com/story/indias-nppa-extends-pricing-policy-drugs-adding-fuel-price-cap-fire/2014-12-12>. Accessed September 28, 2015

75 U.S. Food and Drug Administration

76 Agarwal, A. Ressler, D. Snyder, G. "The current and future state of companion diagnostics," *Pharmacogenomics and Personalized Medicine*, Dove Press, March 31, 2015

77 <http://dictionary.sensagent.com/Theranostics/en-en/>

78 Agarwal, A. Ressler, D. Snyder, G. "The current and future state of companion diagnostics," *Pharmacogenomics and Personalized Medicine*, Dove Press, March 31, 2015

79 "Hype Cycle in Life Sciences," Gartner, 2014

80 *International Comparison of Pharmaceutical Practices and Functions of Pharmaceutical Wholesalers*, The Federation of Japan Pharmaceutical Wholesaler Association, 2013

81 "Hype Cycle in Life Sciences," Gartner, 2014

82 *Health system analytics: The missing key to unlock value-based care*, Deloitte Center for Health Solutions, 2015, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/health-system-analytics.html>

83 *Global Human Capital Trends 2015: Leading in the new world of work*, Deloitte University Press, 2015, <http://www2.deloitte.com/us/en/pages/human-capital/articles/introduction-human-capital-trends.html>

84 Ibid

85 Deloitte's 2015 *Global Human Capital Trends* report is one of the largest longitudinal studies of talent, leadership, and HR challenges and readiness around the world. The research described in this report involved surveys and interviews with more than 3,300 business and HR leaders from 106 countries.

86 *Global Human Capital Trends 2015: Leading in the new world of work*, Deloitte University Press, 2015, <http://www2.deloitte.com/us/en/pages/human-capital/articles/introduction-human-capital-trends.html>

87 *World Preview 2015, Outlook to 2020*, EvaluatePharma, June 2014

88 Ibid

89 <http://www.ibef.org/industry/indian-pharmaceuticals-industry-analysis-presentation>; [http://articles.economicstimes.indiatimes.com/2015-06-17/news/63540280\\_1\\_125-crore-180-crore-20-crore](http://articles.economicstimes.indiatimes.com/2015-06-17/news/63540280_1_125-crore-180-crore-20-crore)

90 "Collaboration and innovation: Ending the 17-year 'valley of death' in getting treatments to patients," *Health Care Current*, Deloitte Center for Health Solutions, September 29, 2015, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/health-care-current-september29-2015.html?id=us:em:na:hcc:eng:lsch:092915#1>. Accessed September 29, 2015

91 Sairamesh Jakka and Michael Rossbach, "An economic perspective on personalized medicine," *The HUGO Journal* 7, no. 1 (2013): DOI: 10.1186/1877-6566-7-1. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015

- <sup>92</sup> Hirsch, Balu, and Schulman, "The Impact of Specialty Pharmaceuticals as Drivers of Health Care Costs," pp. 1714-1720. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015
- <sup>93</sup> Scott D. Ramsey, David Veenstra, Sean R. Tunis, Louis Garrison, John J. Crowley, and Laurence H. Baker, "How Comparative Effectiveness Research Can Help Advance 'Personalized Medicine' in Cancer Treatment," *Health Affairs* 30, no. 12 (2011): pp2259-2268, DOI : 10.1377/hlthaff.2010.0637. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015
- <sup>94</sup> Allen M. Speigel and Meredith Hawkins, "'Personalized Medicine' to Identify Genetic Risks for Type 2 Diabetes and Focus Prevention: Can It Fulfill Its Promise?" *Health Affairs* 31, no. 1 (2012): pp 43-49, DOI: 10.1377/hlthaff.2011.1054. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015
- <sup>95</sup> The Express Scripts Labs, "2014 Drug Trend Report," March 2015, <http://lab.express-scripts.com/drug-trend-report>, accessed March 2015. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015
- <sup>96</sup> Joshua P. Cohen and Abigail E. Felix, "Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement," *Journal of Personalized Medicine* 4, (2014): pp. 163-175; DOI: 10.3390/jpm402016. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015
- <sup>97</sup> *Succeeding with Digital Health: Winning Offerings and Digital Transformation*, Arthur D Little
- <sup>98</sup> Rock Health, Digital health funding: year in review 2014, January 2015, p. 10, <http://www.slideshare.net/fullscreen/RockHealth/rock-health-2014-year-in-review-funding-1/3>, accessed March 2015
- <sup>99</sup> Joseph Kvedar, Molly Joel Coye, and Wendy Everett, "Connected Health: A Review of Technologies and Strategies to Improve Patient Care with Telemedicine and Telehealth," *Health Affairs* 33, no.2 (2014): pp. 194-199, DOI: 10.1377/hlthaff.2013.0992. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015
- <sup>100</sup> *2015 Survey of US Health Care Consumers*, Deloitte Center for Health Solutions, 2015
- <sup>101</sup> Next-generation "smart" MedTech devices: *Preparing for an increasingly intelligent future*, Deloitte Center for Health Solutions, 2015, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/smart-medtech-increasingly-intelligent-future.html>
- <sup>102</sup> Epocrates. Epocrates 2013 mobile trends report: maximizing multi-screen engagement among clinicians. Epocrates: An Athena health Company (pp. 1-10) [http://www.epocrates.com/oldsite/statistics/2013%20Epocrates%20Mobile%20Trends%20Report\\_FINAL.pdf](http://www.epocrates.com/oldsite/statistics/2013%20Epocrates%20Mobile%20Trends%20Report_FINAL.pdf). Excerpted from *Next-generation "smart" MedTech devices: Preparing for an increasingly intelligent future*, Deloitte Center for Health Solutions, 2015
- <sup>103</sup> Next-generation "smart" MedTech devices: *Preparing for an increasingly intelligent future*, Deloitte Center for Health Solutions, 2015, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/smart-medtech-increasingly-intelligent-future.html>
- <sup>104</sup> Ibid
- <sup>105</sup> ROCK Health, "The future of biosensing wearables," June 2014, <http://www.slideshare.net/RockHealth/the-future-of-biosensing-wearables-by-rockhealth>, accessed March 2015. Excerpted from *The convergence of health care trends: Innovation strategies for emerging opportunities*, Deloitte Center for Health Solutions, 2015
- <sup>106</sup> Ibid
- <sup>107</sup> Research department of China International Capital Corporation Limited (CICC); National Health and Family Planning Commission of China (NHFPCC)
- <sup>108</sup> *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015
- <sup>109</sup> *EP Vantage MedTech Half-Year Review 2015*, Evaluate Ltd., July 2015  
<http://www.evaluategroup.com/public/Reports/EPVantage-MedTech-HalfYear-Review-2015.aspx>
- <sup>110</sup> *EP Vantage MedTech Half-Year Review 2015*, Evaluate Ltd., July 2015  
<http://www.evaluategroup.com/public/Reports/EPVantage-MedTech-HalfYear-Review-2015.aspx>
- <sup>111</sup> Thomson Reuters
- <sup>112</sup> "Acquisition of rights to an anti-coagulant product from Novartis," Aspen Holdings news release, January 26, 2015, <http://www.aspenpharma.com/2015/01/acquisition-of-rights-to-an-anti-coagulant-product-from-novartis/>. Accessed September 9, 2015
- <sup>113</sup> "Aspen acquires GSK injectable thrombosis brands," Bloomberg Business, September 30, 2013, <http://www.bloomberg.com/news/2013-09-30/aspen-acquires-gsk-injectable-thrombosis-brands-for-970-million.html>. Accessed September 9, 2015
- <sup>114</sup> "Novartis Signs On to License Google's Glucose-Monitoring Contact Lenses," *BioITWorld*, July 16, 2014, <http://www.bio-itworld.com/els/2014/7/16/novartis-signs-on-license-google-glucose-monitoring-contact-lenses.html>. Accessed September 9, 2015
- <sup>115</sup> "AmerisourceBergen spends \$100M for stake in Brazilian firm," *Philadelphia Business Journal*, March 24, 2014, <http://www.bizjournals.com/philadelphia/blog/health-care/2014/03/amerisourcebergen-goes-shopping-in-brazil.html>. Accessed September 9, 2015
- <sup>116</sup> Ibid
- <sup>117</sup> *Healthcare and Life Sciences Predictions 2020: A bold future?* U.K. Deloitte Centre for Health Solutions, 2014, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/healthcare-and-life-sciences-predictions-2020.html>
- <sup>118</sup> Ibid
- <sup>119</sup> "Serialization – Pharma Faces 2015 Deadline," *Pharmaceutical Online*, March 4, 2014, <http://www.pharmaceuticalonline.com/doc/serialization-pharma-faces-deadline-0001>. Accessed September 19, 2015
- <sup>120</sup> Ibid
- <sup>121</sup> "Serialization – Pharma Faces 2015 Deadline," *Pharmaceutical Online*, March 4, 2014, <http://www.pharmaceuticalonline.com/doc/serialization-pharma-faces-deadline-0001>. Accessed September 19, 2015
- <sup>122</sup> FDA website, <<http://www.fda.gov/biologicsbloodvaccines/internationalactivities/ucm356603.htm>>
- <sup>123</sup> Ibid
- <sup>124</sup> *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

125 Ibid

126 2o Informe de Labores de la COFEPRIS. September 2013 – August 2014. México

127 <http://timesofindia.indiatimes.com/india/Bar-code-o-drug-packaging-to-track-and-trace-authenticity/articleshow/46560914.cms>

128 - [http://articles.economicstimes.indiatimes.com/2015-06-24/news/63783251\\_1\\_commerce-ministry-exporters-pilot-project](http://articles.economicstimes.indiatimes.com/2015-06-24/news/63783251_1_commerce-ministry-exporters-pilot-project)

129 "Shifting risks and IT complexities create demands for new enterprise security strategies," *IDC Health Insights*, February 2014; *Cyber & insider risk at a glance: the pharmaceutical industry*, Deloitte

130 Ibid

131 [http://articles.economicstimes.indiatimes.com/2014-05-20/news/49974576\\_1\\_strong-patent-laws-ipr-patent-protection](http://articles.economicstimes.indiatimes.com/2014-05-20/news/49974576_1_strong-patent-laws-ipr-patent-protection)

132 Agarwal, A. Ressler, D. Snyder, G. "The current and future state of companion diagnostics," *Pharmacogenomics and Personalized Medicine*, Dove Press, March 31, 2015

133 *Healthcare and Life Sciences Predictions 2020: Supply Chain Supplement*, Deloitte UK Centre for Health Solutions, 2014

134 *Global Human Capital Trends 2015: Leading in the new world of work*, Deloitte University Press, 2015, <http://www2.deloitte.com/us/en/pages/human-capital/articles/introduction-human-capital-trends.html>

135 *Duke Translational Medicine Institute, Translational Medicine at Duke*: [http://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=2329&context=faculty\\_scholarship](http://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=2329&context=faculty_scholarship)

136 "Collaboration and innovation: Ending the 17-year 'valley of death' in getting treatments to patients," *Health Care Current*, Deloitte Center for Health Solutions, September 29, 2015, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/health-care-current-september29-2015.html?id=us:em:na:hcc:eng:shc:092915#1>. Accessed September 29, 2015

137 *Next-generation "smart" MedTech devices: Preparing for an increasingly intelligent future*, Deloitte Center for Health Solutions, 2015, <http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/smart-medtech-increasingly-intelligent-future.html>

138 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

139 Ibid

140 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

141 Ibid

142 *Industry Report: Healthcare, United States of America*, The Economist Intelligence Unit, June 2015

143 *Industry Report: Healthcare, Brazil*, The Economist Intelligence Unit, June 2015

144 Ibid

145 EIU Data tool, accessed on 10 September 2015; "Desperate times, desperate moves," *The Economist*, September 5, 2015; EIU, *Country Report- Brazil*, August 2015

146 "Brazil's economy enters recession," BBC News, 28 August 28, 2015

147 [http://mim.promexico.gob.mx/work/sites/mim/resources/LocalContent/374/2/DS\\_Turismo\\_salud\\_ES.pdf](http://mim.promexico.gob.mx/work/sites/mim/resources/LocalContent/374/2/DS_Turismo_salud_ES.pdf)

148 <http://www.elfinanciero.com.mx/economia/mexico-apuesta-a-ser-el-quiروفano-de-eu-coparmex.html>

149 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

150 Ibid

151 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

152 *Industry Report: Healthcare, France*, The Economist Intelligence Unit, June 2015

153 Ibid

154 *Industry Report: Healthcare, Germany*, The Economist Intelligence Unit, June 2015

155 Ibid

156 *Industry Report: Healthcare, Germany*, The Economist Intelligence Unit, June 2015

157 Ibid

158 *Industry Report: Healthcare, Germany*, The Economist Intelligence Unit, June 2015

159 *Industry Report: Healthcare, Russia*, The Economist Intelligence Unit, June 2015

160 Ibid

161 *Industry Report: Healthcare, South Africa*, The Economist Intelligence Unit, May 2015

162 Ibid

163 "South Africa Pharmaceuticals & Healthcare Report," BMI Research, July 2, 2015

164 *Industry Report: Healthcare, Switzerland*, The Economist Intelligence Unit, July 2015, citing the European Federation of Pharmaceutical Industries and Associations (EFPIA)

165 *Industry Report: Healthcare, Switzerland*, The Economist Intelligence Unit, July 2015

166 Ibid

167 Ibid

168 <http://www.genomicsengland.co.uk/the-100000-genomes-project/>

169 <https://www.gov.uk/government/publications/genomics-industry-study-uk-market-analysis>

170 <http://www.genomicsengland.co.uk/the-100000-genomes-project/>

171 UK Pharmaceutical Industry Outlook – 2015 see also: <http://www.protelprojects.com/2015/05/uk-pharmaceutical-industry-outlook-2015/>

172 Ibid

173 <http://www.espicom.com/uk-medical-device-market.html>

174 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

175 Ibid

176 *World industry outlook: Healthcare and pharmaceuticals*, The Economist Intelligence Unit, September 2015

177 "Does China yuan devaluation mean more downbeat pharma earnings?" *FiercePharmaAsia*, August 17, 2015

<sup>178</sup> "J&J CEO Gorsky sees 'new horizon' in China, despite slowing growth," FiercePharma, March 26 2015 & <http://www.innoventbio.com/en/News.aspx?key=search&id=1263&type=%e6%96%b0%e9%97%bb%e4%b8%ad%e5%bf%83>

<sup>179</sup> *Industry Report: Healthcare, India*, The Economist Intelligence Unit, July 2015

<sup>180</sup> *Ibid*

<sup>181</sup> <http://indianexpress.com/article/business/economy/govt-gets-nppa-to-back-off-controls-on-7-of-market-to-go/>. Also [http://articles.economictimes.indiatimes.com/2015-02-25/news/59500075\\_1\\_cells-medicines-national-pharmaceutical-pricing-authority](http://articles.economictimes.indiatimes.com/2015-02-25/news/59500075_1_cells-medicines-national-pharmaceutical-pricing-authority)

<sup>182</sup> *Industry Report: Healthcare, Japan*, The Economist Intelligence Unit, June 2015

<sup>183</sup> *Ibid*

<sup>184</sup> *Industry Report: Healthcare, Japan*, The Economist Intelligence Unit, June 2015

<sup>185</sup> *Ibid*

<sup>186</sup> *Industry Report: Healthcare, Indonesia*, The Economist Intelligence Unit, June 2015

<sup>187</sup> *Ibid*

**About Deloitte**

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a U.K. private company limited by guarantee (“DTTL”, its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see [www.deloitte.com/about](http://www.deloitte.com/about) for a detailed description of DTTL and its member firms.

Deloitte provides audit, consulting, financial advisory, risk management, tax and related services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries and territories, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte’s more than 200,000 professionals, all committed to making an impact that matters.

**Disclaimer**

This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

**About Life Sciences and Health Care at Deloitte Touche Tohmatsu Limited**

The Deloitte Touche Tohmatsu Limited’s life sciences and health care (LSHC) industry group is composed of more than 9,000 professionals in more than 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information about the DTTL LSHC industry group, email [dttlshc@deloitte.com](mailto:dttlshc@deloitte.com) or access [www.deloitte.com/lifesciences](http://www.deloitte.com/lifesciences).